Overview
JC virus (JCV) and BK virus (BKV) are human polyomaviruses belonging to the Polyomaviridae family. These are small, non-enveloped, double-stranded DNA viruses that are widely prevalent in the human population. Primary infection usually occurs during childhood and remains asymptomatic or causes mild illness that often goes unnoticed. After the initial infection, both viruses persist lifelong in a latent state, mainly in the kidneys, central nervous system, and lymphoid tissues. Reactivation of these viruses occurs predominantly in individuals with compromised immunity. Clinically, BKV is primarily associated with nephropathy, while JCV is linked to progressive multifocal leukoencephalopathy. Both viruses have also been reported in association with certain human tumors.
Symptoms
Clinical manifestations vary depending on the virus involved and the degree of immunosuppression present.
JC Virus
Immunosuppression can reactivate JCV, allowing it to migrate to the central nervous system, particularly the brain. The virus infects and destroys oligodendrocytes, leading to lytic infection and demyelination of cerebral white matter at multiple sites. Patients may present with visual field defects, mental status changes, progressive weakness, and ataxia. Historically, the prognosis of PML was poor; however, outcomes have improved with immune reconstitution therapies such as HAART in HIV-infected individuals.
BK Virus
BKV reactivation commonly occurs in immunocompromised patients, especially kidney transplant recipients. The virus replicates within renal tubular epithelial cells, causing cell death, interstitial nephritis, and inflammation, leading to polyomavirus-associated nephropathy. Clinically, this condition is often suspected due to rising serum creatinine levels and can progress to graft dysfunction or graft loss if not identified early.
Causes
Primary infection with JC and BK viruses usually occurs during childhood. BKV enters the body through mucosal contact involving the oral, gastrointestinal, or respiratory tract and subsequently establishes latency in the kidney and uroepithelial cells following viremia. The exact route of JCV entry remains unclear, but it is believed to occur through contaminated food or water during early life. Once acquired, JCV may persist in the urinary tract, bone marrow, tonsils, or brain. Disease develops when latent viruses reactivate due to impaired immune function.
Risk Factors
The principal risk factor for JC and BK virus reactivation is immunosuppression. This includes conditions such as HIV infection, organ transplantation, bone marrow transplantation, autoimmune disorders, and prolonged use of immunosuppressive medications. The likelihood and severity of infection are directly proportional to the degree of immunosuppression. Renal transplant recipients are particularly susceptible to BKV-associated nephropathy, while severely immunocompromised individuals are at higher risk for JCV-associated PML.
Prevention
There is no specific vaccine or targeted antiviral therapy available for JC or BK virus infections. Prevention focuses on early detection and vigilant monitoring in high-risk populations. Quantitative and qualitative monitoring of viral DNA in urine, blood, plasma, or cerebrospinal fluid using molecular techniques such as PCR enables early identification of viral reactivation. Proper sample collection, storage, and timely transportation are essential to maintain sample integrity. In transplant recipients, early viral detection and appropriate modification of immunosuppressive therapy play a crucial role in preventing disease progression and reducing the risk of severe complications.
